William Blair Has Bearish Outlook for Biogen FY2027 Earnings

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at William Blair reduced their FY2027 earnings per share estimates for Biogen in a report released on Wednesday, April 23rd. William Blair analyst M. Minter now expects that the biotechnology company will earn $16.77 per share for the year, down from their previous estimate of $17.41. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen’s FY2028 earnings at $17.66 EPS and FY2029 earnings at $18.03 EPS.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

Other equities research analysts also recently issued reports about the stock. Scotiabank decreased their price target on shares of Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a research note on Thursday, February 13th. Sanford C. Bernstein assumed coverage on shares of Biogen in a research report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 target price for the company. The Goldman Sachs Group lowered their price objective on Biogen from $219.00 to $197.00 and set a “buy” rating for the company in a research note on Wednesday. Canaccord Genuity Group cut their target price on Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, HC Wainwright lowered their price target on Biogen from $300.00 to $241.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Eighteen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $211.37.

Biogen Trading Down 0.6 %

Shares of BIIB stock opened at $118.84 on Friday. The company has a market cap of $17.40 billion, a P/E ratio of 10.62, a PEG ratio of 1.51 and a beta of 0.06. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The stock has a 50 day simple moving average of $132.47 and a two-hundred day simple moving average of $149.14. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35.

Insider Activity at Biogen

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the sale, the director now owns 11,318 shares of the company’s stock, valued at $1,697,926.36. The trade was a 43.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Biogen

Large investors have recently made changes to their positions in the stock. Inspire Trust Co. N.A. boosted its stake in Biogen by 58.5% in the 3rd quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock worth $2,113,000 after purchasing an additional 4,025 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Biogen by 0.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock worth $6,646,000 after buying an additional 111 shares in the last quarter. Amundi boosted its position in shares of Biogen by 35.6% in the fourth quarter. Amundi now owns 1,216,990 shares of the biotechnology company’s stock valued at $183,461,000 after acquiring an additional 319,478 shares during the period. Centre Asset Management LLC grew its stake in Biogen by 7.7% during the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock valued at $7,880,000 after acquiring an additional 3,698 shares in the last quarter. Finally, Integrated Quantitative Investments LLC bought a new stake in Biogen during the 4th quarter worth approximately $407,000. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.